Government-Owned Inventions; Availability for Licensing, 52549-52551 [06-7439]

Download as PDF 52549 Federal Register / Vol. 71, No. 172 / Wednesday, September 6, 2006 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Submission for OMB Review; Comment Request; Preventing Motor Vehicle Crashes Among Young Drivers Summary: Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institute of Child Health and Human Development (NICHD), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the Federal Register on June 13, 2006, page 34142, and allowed 60-days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number. Proposed Collection Title: Preventing Motor Vehicle Crashes Among Young Drivers, OMB No. 0925–new. Type of Information Collection Request: New. Need and Use of Information Collection: Motor vehicle crash risk is particularly elevated among novice young drivers during the first six months and 1000 miles of independent driving. Previously, researchers in the Prevention Research Branch of the NICHD have demonstrated the efficacy of the Checkpoints Program for increasing parental management of teen driving and reducing exposure to high risk driving conditions during the first 12 months after licensure. The current Estimated number of respondents Type of respondents research seeks to test the effectiveness of providing an educational program entitled The Checkpoints Program to facilitate parental management of teen driving when delivered at motor vehicle administration offices at the time the teen obtains a permit, at the time of license, or at both permit and license. Frequency of Response: 3 times over two years. Affected Public: Individuals or households. Type of Respondents: Adolescents and parents/guardians. The annual reporting burden is as follows: Estimated Number of Respondents: 4000; Estimated Number of Responses per Respondent: 3; Average Burden Hours Per Response: 35; and Estimated Total Annual Burden Hours Requested: 4,200. The annualized cost to respondents is estimated at: $42,000 (based on $10 per hour). There are no Capital Costs to report. There are no Operating or Maintenance Costs to report. Estimated number of responses per respondent Average burden hours per response Estimated total annual burden hours requested 2000 2000 3 3 .35 .35 2100 2100 Total .......................................................................................................... rwilkins on PROD1PC63 with NOTICES Parents/guardians ............................................................................................ Teens ............................................................................................................... 4000 3 .35 4200 Request for Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive VerDate Aug<31>2005 18:44 Sep 05, 2006 Jkt 208001 Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Bruce Simons-Morton, Chief, Prevention Research Branch, DESPR, NICHD, NIH, 6100 Executive Blvd., Rm 7B05, MSC 7510, Bethesda, MD 20892–7510; (301) 496–5674; e-mail: mortonb@mail.nih.gov. Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication. Dated: August 25, 2006. Paul Johnson, Project Clearance Liaison, NICHD, National Institutes of Health. [FR Doc. E6–14680 Filed 9–5–06; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ E:\FR\FM\06SEN1.SGM 06SEN1 Federal Register / Vol. 71, No. 172 / Wednesday, September 6, 2006 / Notices 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Ghost Native-PAGE With Colorless Compound Derived From Coomassie Brilliant Blue rwilkins on PROD1PC63 with NOTICES Description of Technology: Protein staining dyes such as serva blue G or Coomassie blue are used to enhance the separation of protein complexes by binding to the proteins and differentially enhancing the net charge of the complexes improving the Applications: Alzheimer’s disease diagnostics; Parkinson’s disease diagnostics. Market: Protein-protein interaction biochemistry. Development Status: Early-stage. Inventors: Robert Balaban (NHLBI), Gary Griffiths (NHLBI), Ksenia Blinova (NHLBI), et al. Publications: 1. MM Camacho-Carvajal, et al. Twodimensional Blue native/SDS gel electrophoresis of multi-protein complexes from whole cellular lysates: a proteomics approach. Mol Cell Proteomics. 2004 Feb; 3(2):176–182. 2. R Van Coster, et al. Blue native polyacrylamide gel electrophoresis: a powerful tool in diagnosis of oxidative phosphorylation defects. Pediatr Res. 2001 Nov; 50(5):658–665. 3. I Whittig and H Schagger. Advantages and limitations of clearnative PAGE. Proteomics. 2005 Nov; 5(17):4338–4346. Patent Status: U.S. Provisional Application No. 60/835,069 filed 03 VerDate Aug<31>2005 18:44 Sep 05, 2006 Jkt 208001 separation of the complexes using electrophoresis procedures. However, the intense blue color of Coomassie stains interferes with immunobloting and in gel colormetric or fluorescent studies. Available for licensing and commercial development is a colorless molecule that will bind and enhance the differential surface charge on protein complexes. The molecule has been demonstrated to work as well as Coomassie blue but will not interfere in gel assays critical for most investigations. This approach provides biochemists interested in protein complexes in biological tissues with the ability to separate protein complexes and perform in gel assays saving time and resources in this important emerging field. The compound and methods of its use is for polyacrylamide gel electrophoresis (PAGE) and related gel techniques for the analysis of protein complexes and defects in the same. Such analysis can be extended to the detection of various diseases, e.g., Alzheimer’s disease or Parkinson’s disease. One such compound has the following formula: Aug 2006 (HHS Reference No. E–218– 2006/0-US–01). Licensing Status: Available for exclusive or non-exclusive licensing. Licensing Contact: Michael A. Shmilovich, Esq.; 301/435–5019; shmilovm@mail.nih.gov. biomarker of disease and certain neurological disorders. This comprises performing in vivo magnetization transfer spectroscopy, and determining the change in magnetic resonance signal intensity of reactants in AST catalyzed reaction. AST activity is known to change as a result of tissue damage and necrosis in a variety of diseases. AST activity is routinely assessed in serum of patients as a non-invasive means of identifying and following up on disease progression. Furthermore, brain levels of AST are altered in certain diseases such as Huntington’s Disease, olivopontocerebellar atrophy and epilepsy, but the blood-brain barrier prevents AST from entering serum and being readily measured. Brain AST levels in living patients can be measured by brain biopsies, which are expensive and dangerous. This invention overcomes this problem by measuring AST activity in the brain by using magnetization transfer effect. This In Vivo Non-Invasive Diagnostic Method Using Magnetic Resonance Spectroscopy of Aspartate Transaminase Description of Technology: This invention describes a method for noninvasively diagnosing various diseases using magnetic resonance spectroscopy of aspartate transaminase (AST). The diagnostic market is a multi-billion dollar market, with a need for more efficient non-invasive techniques, markers and methods of diagnosis. In particular, this is a novel noninvasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, including the brain, as a PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 E:\FR\FM\06SEN1.SGM 06SEN1 EN06SE06.002</GPH> 52550 Federal Register / Vol. 71, No. 172 / Wednesday, September 6, 2006 / Notices can help diagnose or follow up on the progress of a variety of diseases, including Huntington’s Disease, olivopontocerebellar atrophy, epilepsy, schizophrenia, as well as hepatitis, cirrhosis, cholangitis, Gilbert’s diseases, muscular dystrophy, leukemia, kidney inflammation, cardiac infarction, or the presence of a tumor. Thus, tissue AST activity may become a novel marker of brain disorders which has been inaccessible using current clinical technologies. Applications and Market: Diagnosis and monitoring disease status in a variety of diseases, including Huntington’s Disease, olivopontocerebellar atrophy, epilepsy, schizophrenia, as well as hepatitis, cirrhosis, cholangitis, Gilbert’s diseases, muscular dystrophy, leukemia, kidney inflammation, cardiac infarction, or the presence of a tumor. The diagnostic market is a multi-billion dollar market, with a need for more efficient noninvasive techniques, markers and new methods of diagnosis. Patent Status: U.S. Patent Application No. 11/356,214 filed 21 Feb 2006 (HHS Reference No. E–231–2005/0–US–02). Inventors: Dr. Jun Shen (NIMH). Publication: J Shen. In vivo carbon-13 magnetization transfer effect: detection of aspartate aminotransferase reaction. Magn Reson Med. 2005 Dec; 54(6):1321– 1326. Licensing Status: Available for exclusive or non-exclusive licensing. Licensing Contact: Chekesha Clingman, Ph.D.; 301/435–5018; clingman@mail.nih.gov. Dated: August 29, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 06–7439 Filed 9–5–06; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health rwilkins on PROD1PC63 with NOTICES National Center for Complementary & Alternative Medicine; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Advisory Council for Complementary and Alternative Medicine, September 8, 2006, 9 a.m. to September 8, 2006, 4 p.m., National Institutes of Health, Neuroscience Building, 6001 Executive Boulevard, Rooms C & D, Rockville, MD 20852, which was published in the VerDate Aug<31>2005 18:44 Sep 05, 2006 Jkt 208001 Federal Register on July 28, 2006, 71 FR 42860. This meeting is being amended due to the start time change for the Open session from 2 p.m. to 1:30 p.m. The meeting is partially Closed to the public. Dated: August 28, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–7436 Filed 9–5–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Mental Health; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel; NIMH Eating Disorders Grant Application Review. Date: September 29, 2006. Time: 1 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Bettina D. Osborn, Ph.D., Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6154, MSC 9609, Rockville, MD 20852–9609, 301–443–1178, acunab@mail.nih.gov. Name of Committee: National Institute of Mental Health Special Emphasis Panel; Mental Health Centers for Intervention Development and Applied Research (CIDAR). Date: October 12–13, 2006. Time: 9 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Park Hotel, 8400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: A. Roger Little, Ph.D., Scientific Review Administrator, Division of Extramural Activities, National Institute of Frm 00029 Fmt 4703 Sfmt 4703 Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6157, MSC 9609, Rockville, MD 20852–9609, 301–402–5844, alittle@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS) Dated: August 28, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–7434 Filed 9–5–06; 8:45 am] BILLING CODE 4140–01–M National Institutes of Health PO 00000 52551 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting Notice is hereby given of changes in the meeting of the National Diabetes and Digestive and Kidney Diseases Advisory Council, September 20, 2006, 8:30 a.m. to September 21, 2006, 12 p.m., National Institutes of Health, Building 31, 31 Center Drive, Bethesda, MD 20892, which was published in the Federal Register on August 18, 2006, 71 FR 47820–47821. Name of Committee: National Diabetes and Digestive and Kidney Diseases Advisory Council. Date: September 20–21, 2006. Open: September 20, 2006, 8:30 a.m. to 12 p.m. Agenda: To present the Director’s Report and other scientific presentations. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892. Open: September 20, 2006, 4 p.m. to 5 p.m. Agenda: Report from the NIH Director. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892. Closed: September 21, 2006, 9:45 a.m. to 10:15 a.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892. Open: September 21, 2006, 10:15 a.m. to 12 p.m. Agenda: Continuation of the Director’s Report and other scientific presentations. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892. Contact Person: Brent B. Stanfield, Ph.D., Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., E:\FR\FM\06SEN1.SGM 06SEN1

Agencies

[Federal Register Volume 71, Number 172 (Wednesday, September 6, 2006)]
[Notices]
[Pages 52549-52551]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-7439]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/

[[Page 52550]]

496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement 
will be required to receive copies of the patent applications.

Ghost Native-PAGE With Colorless Compound Derived From Coomassie 
Brilliant Blue

    Description of Technology: Protein staining dyes such as serva blue 
G or Coomassie blue are used to enhance the separation of protein 
complexes by binding to the proteins and differentially enhancing the 
net charge of the complexes improving the separation of the complexes 
using electrophoresis procedures. However, the intense blue color of 
Coomassie stains interferes with immunobloting and in gel colormetric 
or fluorescent studies. Available for licensing and commercial 
development is a colorless molecule that will bind and enhance the 
differential surface charge on protein complexes. The molecule has been 
demonstrated to work as well as Coomassie blue but will not interfere 
in gel assays critical for most investigations. This approach provides 
biochemists interested in protein complexes in biological tissues with 
the ability to separate protein complexes and perform in gel assays 
saving time and resources in this important emerging field.
    The compound and methods of its use is for polyacrylamide gel 
electrophoresis (PAGE) and related gel techniques for the analysis of 
protein complexes and defects in the same. Such analysis can be 
extended to the detection of various diseases, e.g., Alzheimer's 
disease or Parkinson's disease. One such compound has the following 
formula:
[GRAPHIC] [TIFF OMITTED] TN06SE06.002

    Applications: Alzheimer's disease diagnostics; Parkinson's disease 
diagnostics.
    Market: Protein-protein interaction biochemistry.
    Development Status: Early-stage.
    Inventors: Robert Balaban (NHLBI), Gary Griffiths (NHLBI), Ksenia 
Blinova (NHLBI), et al.
    Publications:
    1. MM Camacho-Carvajal, et al. Two-dimensional Blue native/SDS gel 
electrophoresis of multi-protein complexes from whole cellular lysates: 
a proteomics approach. Mol Cell Proteomics. 2004 Feb; 3(2):176-182.
    2. R Van Coster, et al. Blue native polyacrylamide gel 
electrophoresis: a powerful tool in diagnosis of oxidative 
phosphorylation defects. Pediatr Res. 2001 Nov; 50(5):658-665.
    3. I Whittig and H Schagger. Advantages and limitations of clear-
native PAGE. Proteomics. 2005 Nov; 5(17):4338-4346.
    Patent Status: U.S. Provisional Application No. 60/835,069 filed 03 
Aug 2006 (HHS Reference No. E-218-2006/0-US-01).
    Licensing Status: Available for exclusive or non-exclusive 
licensing.
    Licensing Contact: Michael A. Shmilovich, Esq.; 301/435-5019; 
shmilovm@mail.nih.gov.

In Vivo Non-Invasive Diagnostic Method Using Magnetic Resonance 
Spectroscopy of Aspartate Transaminase

    Description of Technology: This invention describes a method for 
non-invasively diagnosing various diseases using magnetic resonance 
spectroscopy of aspartate transaminase (AST). The diagnostic market is 
a multi-billion dollar market, with a need for more efficient non-
invasive techniques, markers and methods of diagnosis.
    In particular, this is a novel non-invasive method for using 
carbon-13 magnetization transfer effects to determine and evaluate in 
vivo aspartate transaminase (AST) activity and levels in an organ, 
including the brain, as a biomarker of disease and certain neurological 
disorders. This comprises performing in vivo magnetization transfer 
spectroscopy, and determining the change in magnetic resonance signal 
intensity of reactants in AST catalyzed reaction.
    AST activity is known to change as a result of tissue damage and 
necrosis in a variety of diseases. AST activity is routinely assessed 
in serum of patients as a non-invasive means of identifying and 
following up on disease progression. Furthermore, brain levels of AST 
are altered in certain diseases such as Huntington's Disease, 
olivopontocerebellar atrophy and epilepsy, but the blood-brain barrier 
prevents AST from entering serum and being readily measured. Brain AST 
levels in living patients can be measured by brain biopsies, which are 
expensive and dangerous. This invention overcomes this problem by 
measuring AST activity in the brain by using magnetization transfer 
effect. This

[[Page 52551]]

can help diagnose or follow up on the progress of a variety of 
diseases, including Huntington's Disease, olivopontocerebellar atrophy, 
epilepsy, schizophrenia, as well as hepatitis, cirrhosis, cholangitis, 
Gilbert's diseases, muscular dystrophy, leukemia, kidney inflammation, 
cardiac infarction, or the presence of a tumor. Thus, tissue AST 
activity may become a novel marker of brain disorders which has been 
inaccessible using current clinical technologies.
    Applications and Market: Diagnosis and monitoring disease status in 
a variety of diseases, including Huntington's Disease, 
olivopontocerebellar atrophy, epilepsy, schizophrenia, as well as 
hepatitis, cirrhosis, cholangitis, Gilbert's diseases, muscular 
dystrophy, leukemia, kidney inflammation, cardiac infarction, or the 
presence of a tumor. The diagnostic market is a multi-billion dollar 
market, with a need for more efficient non-invasive techniques, markers 
and new methods of diagnosis.
    Patent Status: U.S. Patent Application No. 11/356,214 filed 21 Feb 
2006 (HHS Reference No. E-231-2005/0-US-02).
    Inventors: Dr. Jun Shen (NIMH).
    Publication: J Shen. In vivo carbon-13 magnetization transfer 
effect: detection of aspartate aminotransferase reaction. Magn Reson 
Med. 2005 Dec; 54(6):1321-1326.
    Licensing Status: Available for exclusive or non-exclusive 
licensing.
    Licensing Contact: Chekesha Clingman, Ph.D.; 301/435-5018; 
clingman@mail.nih.gov.

    Dated: August 29, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 06-7439 Filed 9-5-06; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.